Selzentry Side Effects

Generic Name: maraviroc

Note: This document contains side effect information about maraviroc. Some of the dosage forms listed on this page may not apply to the brand name Selzentry.

Some side effects of Selzentry may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to maraviroc: oral tablet

Along with its needed effects, maraviroc (the active ingredient contained in Selzentry) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking maraviroc:

More common
  • Body aches or pain
  • burning or stinging of the skin
  • chills
  • cough producing mucus
  • coughing
  • difficulty with breathing
  • dizziness when getting up suddenly from a lying or sitting position
  • ear congestion
  • headache
  • loss of voice
  • pain or tenderness around the eyes and cheekbones
  • painful blisters on the trunk of the body
  • painful cold sores or blisters on the lips, nose, eyes, or genitals
  • shortness of breath or troubled breathing
  • sneezing
  • sore throat
  • stuffy or runny nose
  • tightness of the chest or wheezing
  • unusual tiredness or weakness
Less common
  • Abdominal or stomach pain or tenderness
  • arm, back, or jaw pain
  • black, tarry stools
  • blood in the urine
  • blurred or double vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • burning, dry, or itching eyes
  • burning, itching, and pain in the hairy areas, pus at the root of the hair
  • change in consciousness
  • chest pain, discomfort, or heaviness
  • choking
  • clay-colored stools
  • cold, clammy skin
  • confusion
  • convulsions
  • dark-colored urine
  • diarrhea
  • dilated neck veins
  • discharge or excessive tearing
  • dizziness
  • drowsiness
  • earache
  • extreme fatigue
  • eye pain
  • fast, weak pulse
  • fever
  • frequent urge to urinate
  • general feeling of discomfort or illness
  • general feeling of tiredness or weakness
  • heavy jaw feeling
  • inability to speak
  • increased frequency of urination
  • irregular breathing
  • itching
  • joint pain
  • light-colored stools
  • lightheadedness
  • loosening of a tooth
  • loss of appetite
  • loss of bladder control
  • loss of taste
  • lumps in the tongue
  • muscle aches, pains, or stiffness
  • muscle cramps or spasms
  • nausea or vomiting
  • nervousness
  • noisy breathing
  • pain or burning during urination
  • pain or discomfort in the arms, jaw, back, or neck
  • pain, swelling, or numbness in the mouth or jaw
  • pale skin
  • pounding in the ears
  • rash
  • redness or swelling in the ear
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • sensitivity of the eye to light
  • severe abdominal or stomach cramps and pain
  • severe or sudden headache
  • shakiness in the legs, arms, hands, or feet
  • shivering
  • skin lumps
  • slow, fast, or irregular heartbeat
  • slurred speech
  • spread of cancer to the liver
  • stiff neck or back
  • stomach lumps
  • stomach pain, continuing
  • sudden loss of consciousness
  • sweating
  • swelling of the face, fingers, feet, or lower legs
  • swollen glands
  • tearing
  • temporary blindness
  • trembling or shaking of the hands or feet
  • trouble sleeping
  • troubled breathing with exertion
  • unable to speak
  • unpleasant breath odor
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • vomiting of blood
  • warts on the genital area
  • watery and severe diarrhea, which may also be bloody
  • weakness in the arms, hands, legs, or feet
  • weakness on one side of the body, sudden and severe
  • weight gain
  • weight loss
  • yellow eyes or skin
Incidence not known
  • Blistering, peeling, or loosening of the skin
  • cough
  • muscle pain
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sores, ulcers, or white spots in the mouth or on the lips

Some side effects of maraviroc may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Difficulty having a bowel movement (stool)
  • difficulty with moving
  • increased or decreased appetite
  • swelling or redness in the joints
Less common
  • Acid or sour stomach
  • belching
  • blistering, crusting, irritation, or reddening of the skin
  • canker sores
  • discouragement
  • feeling sad or empty
  • flushing or redness of the skin
  • heartburn
  • indigestion
  • irritability
  • loss of interest or pleasure
  • redistribution or accumulation of body fat
  • skin rash, encrusted, scaly, and oozing
  • sores, ulcers, or white spots on the lips or tongue or inside the mouth
  • stomach discomfort or upset
  • tiredness
  • trouble in concentrating
  • unusually warm skin

For Healthcare Professionals

Applies to maraviroc: oral tablet

General

The most common side effects reported with twice-daily treatment were cough, pyrexia, upper respiratory tract infections, rash, and dizziness. The most common side effects reported with once-daily dosing were diarrhea, edema, influenza, esophageal candidiasis, sleep disorders, rhinitis, parasomnias, and urinary abnormalities.

Respiratory

Very common (10% or more): Upper respiratory tract infection (23% to 32%), coughing and associated symptoms (14%), bronchitis (7% to 13%)
Common (1% to 10%): Upper respiratory tract signs and symptoms (9%), sinusitis (7%), upper respiratory tract signs and symptoms (6%), nasal congestion and inflammations (4%), breathing abnormalities (4%), paranasal sinus disorders (3%), lower respiratory tract and lung infections (3%), pneumonia (2% or less), influenza (2%)
Frequency not reported: Rhinitis, bronchospasm and obstruction, respiratory tract disorders, epistaxis

Other

Very common (10% or more): Pyrexia (13%)
Common (1% to 10%): Herpes infection (7% to 8%), bacterial infections NEC (6%), herpes zoster/varicella (5%), pain and discomfort (4%), Neisseria infections (3%), viral infections NEC (3%), body temperature perception (3%), ear disorders NEC (3%), otitis media (2%), treponema infections (less than 2%), septic shock (less than 2%)
Frequency not reported: Edema, fatigue, asthenia, hot flushes, condyloma acuminatum

Dermatologic

Severe, potentially life-threatening skin and hypersensitivity reactions were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. In most cases, maraviroc (the active ingredient contained in Selzentry) was coadministered with other drugs associated with such reactions.

Very common (10% or more): Rash (11%)
Common (1% to 10%): Nail and nail bed conditions (excluding infections and infestations; 6%), apocrine and eccrine gland disorders (5%), pruritus (4%), folliculitis (4%), tinea infections (4%), lipodystrophies (3% to 4%), acnes (3%), erythemas (2%), alopecias (2%)
Frequency not reported: Dermatitis, eczema
Postmarketing reports: Severe skin reactions (including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS], toxic epidermal necrolysis)

Hypersensitivity

Severe, potentially life-threatening skin and hypersensitivity reactions were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. In most cases, maraviroc (the active ingredient contained in Selzentry) was coadministered with other drugs associated with such reactions.

Postmarketing reports: Severe hypersensitivity reactions

Gastrointestinal

Very common (10% or more): Flatulence, bloating, and distention (10%)
Common (1% to 10%): Gastrointestinal atonic and hypomotility disorders NEC (9%), constipation (6%), gastrointestinal signs and symptoms NEC (3%), Clostridium difficile colitis (less than 2%)
Frequency not reported: Diarrhea, esophageal candidiasis, gastrointestinal and abdominal pains, dyspeptic signs/symptoms, ulceration stomatitis, nausea, gingivitis, dry mouth, flatulence, vomiting

Nervous system

Common (1% to 10%): Dizziness/postural dizziness (9%), paresthesias and dysesthesias (4% to 5%), sensory abnormalities (4%), disturbances in consciousness (4%), peripheral neuropathies (4%), memory loss (excluding dementia; 3%), cerebrovascular accident (less than 2%), convulsions and epilepsy (less than 2%), tremor (excluding congenital; less than 2%), facial palsy (less than 2%), hemianopia (less than 2%), loss of consciousness (less than 2%), viral meningitis (less than 2%), meningitis (less than 2%), visual field defect (less than 2%)
Frequency not reported: Headache, sleep disorders

Hematologic

Common (1% to 10%): Anemias NEC (8%), decreased absolute neutrophil count (less than 750/mm3; 5.7%), decreased absolute neutrophil count (less than 750/mm3; 4.3%), neutropenias (4%), decreased hemoglobin (less than 7 g/dL; 2.9%), marrow depression (less than 2%), hypoplastic anemia (less than 2%)

Metabolic

Common (1% to 10%): Appetite disorders (8%), elevated amylase (greater than 2 times ULN; 4.3% to 5.7%), elevated lipase (greater than 2 times ULN; 4.9%), elevated creatine kinase (3.9%)
Frequency not reported: Unintentional weight loss (wasting), hyperlipidemia

Psychiatric

Common (1% to 10%): Disturbances in initiating and maintaining sleep (8%), depressive disorders (4%), anxiety symptoms (4%)
Frequency not reported: Parasomnias, somnolence

Musculoskeletal

Common (1% to 10%): Joint-related signs and symptoms (6% to 7%), muscle pains (3%), myositis (less than 2%), infective myositis (less than 2%), osteonecrosis (less than 2%), rhabdomyolysis (less than 2%), increased blood creatine kinase (less than 2%)

Hepatic

Common (1% to 10%): Elevated total bilirubin (greater than 5 times ULN; 5.5%), elevated aspartate transaminase (greater than 5 times ULN; 4% to 4.8%), elevated alanine transaminase (greater than 5 times ULN; 2.6% to 3.9%), hepatic cirrhosis (less than 2%), hepatic failure (less than 2%), cholestatic jaundice (less than 2%), portal vein thrombosis (less than 2%), hypertransaminasemia (less than 2%), jaundice (less than 2%)
Frequency not reported: Hepatotoxicity (sometimes associated with rash and eosinophilia)

Genitourinary

Common (1% to 10%): Bladder and urethral symptoms (4% to 5%), urinary tract signs and symptoms (3%), erection and ejaculation conditions and disorders (3%), anogenital warts (2%)
Frequency not reported: Urinary abnormalities

Cardiovascular

Common (1% to 10%): Vascular hypertensive disorders (3%), unstable angina (less than 2%), acute cardiac failure (less than 2%), coronary artery disease (less than 2%), coronary artery occlusion (less than 2%), endocarditis (less than 2%), myocardial infarction (less than 2%), myocardial ischemia (less than 2%)
Frequency not reported: Postural hypotension, arrhythmia

Oncologic

Common (1% to 10%): Skin neoplasms (3%), abdominal neoplasm (less than 2%), anal cancer (less than 2%), anaplastic large cell lymphomas (T- and null-cell types; less than 2%), malignant bile duct neoplasms (less than 2%), endocrine neoplasms (malignant and unspecified; less than 2%), basal cell carcinoma (less than 2%), Bowen's disease (less than 2%), cholangiocarcinoma (less than 2%), diffuse large B-cell lymphoma (less than 2%), lymphoma (less than 2%), metastases to liver (less than 2%), esophageal carcinoma (less than 2%), nasopharyngeal carcinoma (less than 2%), squamous cell carcinoma (less than 2%), squamous cell carcinoma of skin (less than 2%), tongue neoplasm (unspecified malignant stage; less than 2%)

Ocular

Common (1% to 10%): Conjunctivitis (2%), ocular infections, inflammations, and associated manifestations (2%)
Frequency not reported: Abnormal vision, eye pain

Immunologic

Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, and Guillain-Barre syndrome)

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)